IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Shore, Neal
Stenzl, Arnulf
Pieczonka, Christopher
Klaassen, Zachary
Aronson, William
Karsh, Lawrence
Ryan, Charles
Miskic, Marina
Srinivasan, Shankar
Mohamed, Ateesha
Verholen, Frank
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD34-10
引用
收藏
页码：E586 / E587
页数：2
相关论文
共 50 条
  • [21] Darolutamide for treatment of castration-resistant prostate cancer
    Rhea, L. P.
    Mendez-Marti, S.
    Aragon-Ching, J. B.
    DRUGS OF TODAY, 2020, 56 (03) : 185 - 193
  • [22] EFFICACY AND SAFETY OF DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH AND WITHOUT PRIOR LOCAL THERAPY WITH RADICAL PROSTATECTOMY OR RADIOTHERAPY
    Siemens, David Robert
    Fizazi, Karim
    Shore, Neal D.
    Smith, Matthew R.
    Ortiz, Jorge
    Schmall, Anja
    Srinivasan, Shankar
    Verholen, Frank
    Saar, Matthias
    JOURNAL OF UROLOGY, 2022, 207 (05): : E451 - E451
  • [23] The health inequality impact of darolutamide for nonmetastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
    Janssen, J.
    Flottemesch, T.
    Brewer, I.
    Sullivan, P.
    Partridge, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S962 - S962
  • [24] Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Schultz, Neil M.
    O'Day, Ken
    Sugarman, Rebecca
    Ramaswamy, Krishnan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04): : 538 - 549
  • [25] Management of nonmetastatic castration-resistant prostate cancer
    Traboulsi, Samer L.
    Saad, Fred
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 366 - 371
  • [26] Managing Nonmetastatic Castration-resistant Prostate Cancer
    Mateo, Joaquin
    Fizazi, Karim
    Gillessen, Silke
    Heidenreich, Axel
    Perez-Lopez, Raquel
    Oyen, Wim J. G.
    Shore, Neal
    Smith, Matthew
    Sweeney, Christopher
    Tombal, Bertrand
    Tomlins, Scott A.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2019, 75 (02) : 285 - 293
  • [27] The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
    Tripathy, Sambit
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 293 - 294
  • [28] Effects of prior local therapy by radical prostatectomy or radiotherapy on the efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer from aramis
    Saar, M.
    Fizazi, K.
    Shore, N. D.
    Smith, M. R.
    Damber, J-E
    Semenov, A.
    Ribal Caparros, M. J.
    Birtle, A.
    Rigaud, J.
    Ortiz, J.
    Schmall, A.
    Srinivasan, S.
    Verholen, F.
    EUROPEAN UROLOGY, 2022, 81 : S1423 - S1424
  • [29] Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
    Yildizhan, Mehmet
    Gemalmaz, Hakan
    Ertek, Mehmet Sirin
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (02): : 120 - 127
  • [30] Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Altavilla, Amelia
    Casadei, Chiara
    Lolli, Cristian
    Menna, Cecilia
    Ravaglia, Giorgia
    Gurioli, Giorgia
    Farolfi, Alberto
    Brighi, Nicole
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Schepisi, Giuseppe
    Rossi, Lorena
    Gargiulo, Stefania
    Lisotti, Ivana
    De Giorgi, Ugo
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2091 - 2099
12345